IndexIQ Advisors LLC purchased a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,183 shares of the biotechnology company's stock, valued at approximately $382,000. IndexIQ Advisors LLC owned 0.05% of Arcturus Therapeutics at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC bought a new stake in Arcturus Therapeutics during the 4th quarter valued at approximately $32,000. KRS Capital Management LLC bought a new stake in Arcturus Therapeutics during the 4th quarter valued at approximately $51,000. Daiwa Securities Group Inc. boosted its position in Arcturus Therapeutics by 44.0% during the 1st quarter. Daiwa Securities Group Inc. now owns 3,503 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 1,071 shares in the last quarter. Byrne Asset Management LLC boosted its position in Arcturus Therapeutics by 29.4% during the 1st quarter. Byrne Asset Management LLC now owns 4,000 shares of the biotechnology company's stock valued at $108,000 after acquiring an additional 910 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Arcturus Therapeutics during the 4th quarter valued at approximately $158,000. Hedge funds and other institutional investors own 80.10% of the company's stock.Get Arcturus Therapeutics alerts:
Analysts Set New Price Targets
Several analysts have weighed in on ARCT shares. Citigroup cut Arcturus Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $86.00 to $29.00 in a research report on Thursday, April 21st. HC Wainwright dropped their price target on Arcturus Therapeutics from $25.00 to $19.00 in a research report on Tuesday, May 10th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, May 9th. Barclays dropped their price target on Arcturus Therapeutics from $17.00 to $16.00 and set an "underweight" rating on the stock in a research report on Wednesday. Finally, The Goldman Sachs Group dropped their price target on Arcturus Therapeutics from $14.00 to $8.00 and set a "sell" rating on the stock in a research report on Tuesday, May 24th. Four investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of "Hold" and an average price target of $38.75.
Arcturus Therapeutics Stock PerformanceARCT stock opened at $17.03 on Friday. The stock has a market capitalization of $449.92 million, a PE ratio of -2.71 and a beta of 2.70. Arcturus Therapeutics Holdings Inc. has a 12-month low of $11.70 and a 12-month high of $58.45. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.21. The stock's 50 day simple moving average is $17.06 and its 200 day simple moving average is $20.65.
Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) last released its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.82) earnings per share ( EPS ) for the quarter, beating the consensus estimate of ($1.90) by $1.08. The business had revenue of $27.09 million for the quarter, compared to analysts' expectations of $3.33 million. Arcturus Therapeutics had a negative return on equity of 73.87% and a negative net margin of 407.91%. During the same period in the prior year, the firm posted ($2.07) EPS. As a group, research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -6.71 earnings per share for the current fiscal year.
Arcturus Therapeutics Profile
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Find and Profitably Trade Stocks at 52-Week Lows
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.